CPC C12Q 1/6809 (2013.01) [C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12Q 1/6883 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] | 7 Claims |
1. A method of monitoring disease progression in a subject, the method comprising:
conducting an assay on a sample from a patient to measure expression levels of one or more long non-coding RNA (lncRNA) species selected from the group consisting of ENSG00000272288, ENSG00000111640, ENSG00000237017, ENSG00000249096, ENSG00000271870, ENSG00000272579, ENSG00000233223, ENSG00000267321, ENSG00000263065, ENSG00000228395, ENSG00000264304, ENSG00000261207, ENSG00000245060, ENSG00000228140, ENSG00000261346, ENSG00000242258, ENSG00000272462, ENSG00000225963, ENSG00000267194, ENSG00000260219, ENSG00000237424, ENSG00000249684, ENSG00000273265, ENSG00000256072, ENSG00000272955, ENSG00000251580, ENSG00000272782, ENSG00000260496, ENSG00000271122, ENSG00000223768, ENSG00000262312, ENSG00000244879, ENSG00000223396, ENSG00000257270, ENSG00000258768, ENSG00000243368, ENSG00000224888, and ENSG00000258302;
comparing the expression levels to a reference expression level to determine a differential expression of the lncRNA gene relative to a reference lncRNA expression profile; and
determining disease progression of multiple sclerosis based on the differential expression of the lncRNA gene.
|